Research Article

The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation

Sebastian Steven,1,2 Matthias Oelze,1 Michael Hausding,1 Siyer Roohani,1 Fatemeh Kashani,1 Swenja Kröller-Schön,1 Johanna Helmstädt,1 Thomas Jansen,1 Christine Baum,3 Marc Iglarz,4 Eberhard Schulz,1 Thomas Münzel,1,2,5 and Andreas Daiber1,2,5

1Center for Cardiology, Department of Cardiology, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
2Center of Thrombosis and Hemostasis, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
3Actelion Pharmaceuticals Deutschland GmbH, Konrad-Goldmann-Straße 5b, 79100 Freiburg, Germany
4Pharmacology and Preclinical Development, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland
5Partner Site Rhine-Main, German Center for Cardiovascular Research (DZHK), Langenbeckstr. 1, 55131 Mainz, Germany

Correspondence should be addressed to Andreas Daiber; daiber@uni-mainz.de

Received 25 May 2018; Accepted 17 October 2018; Published 27 December 2018

Academic Editor: Olga Pechanova

Copyright © 2018 Sebastian Steven et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Organic nitrates such as isosorbide-5-mononitrate (ISMN) and isosorbide dinitrate (ISDN) are used for the treatment of patients with chronic symptomatic stable coronary artery disease and chronic congestive heart failure. Limiting side effects of these nitrovasodilators include nitrate tolerance and/or endothelial dysfunction mediated by oxidative stress. Here, we tested the therapeutic effects of the dual endothelin (ET) receptor antagonist macitentan in ISMN- and ISDN-treated animals. Methods and Results. Organic nitrates (ISMN, ISDN, and nitroglycerin (GTN)) augmented the oxidative burst and interleukin-6 release in cultured macrophages, whereas macitentan decreased the oxidative burst in isolated human leukocytes. Male C57BL/6j mice were treated with ISMN (75 mg/kg/d) or ISDN (25 mg/kg/d) via s.c. infusion for 7 days and some mice in addition with 30 mg/kg/d of macitentan (gavage, once daily). ISMN and ISDN in vivo therapy caused endothelial dysfunction but no nitrate (or cross-)tolerance to the organic nitrates, respectively. ISMN/ISDN increased blood nitrosative stress, vascular/cardiac oxidative stress via NOX-2 (fluorescence and chemiluminescence methods), ET1 expression, ET receptor signaling, and markers of inflammation (protein and mRNA level). ET receptor signaling blockade by macitentan normalized endothelial function, vascular/cardiac oxidative stress, and inflammatory phenotype in both nitrate therapy groups. Conclusion. ISMN/ISDN treatment caused activation of the NOX-2/ET receptor signaling axis leading to increased vascular oxidative stress and inflammation as well as endothelial dysfunction. Our study demonstrates for the first time that blockade of ET receptor signaling by the dual endothelin receptor blocker macitentan improves adverse side effects of the organic nitrates ISMN and ISDN.

1. Introduction

Organic nitrates such as glyceryl trinitrate (GTN), isosorbide dinitrate (ISDN), and isosorbide-5-mononitrate (ISMN) still remain the foremost orally available drugs in the treatment of patients with chronic symptomatic stable coronary artery disease, acute myocardial infarction, and chronic congestive heart failure [1–3]. The most limiting side effects include the development of nitrate tolerance and/or endothelial dysfunction, which has been described to occur in response to chronic treatment of humans with GTN, ISDN, and ISMN [2, 4–6]. While the pathophysiology underlying
GTN-induced endothelial dysfunction has been extensively characterized [1, 2], especially regarding the adverse effects on the hemodynamic and autonomic response [7, 8], there are only limited data available to explain why ISMN or ISDN has adverse effects on the vascular endothelium. In contrast to GTN and pentetretinil tetranitrate (PENTN), ISMN and ISDN are not subject to bioactivation by the mitochondrial aldehyde dehydrogenase (ALDH-2) located within mitochondria [9, 10]. Other ALDH isozymes were identified to bioactivate various organic nitrates in vitro [11, 12], and it is postulated that cytosolic ALDH-2 is responsible at least in some cell types (e.g., vascular cells) for GTN bioactivation [13]. ISDN and GTN are supposed to be bioactivated by P450 enzymes [14, 15]. In addition, xanthine oxidoreductase was demonstrated as an ISDN- and ISMN-metabolizing enzyme with higher turnover with xanthine instead of NADH as the source of electrons, although only at suprapharmacological organic nitrate levels [16].

ISMN treatment causes endothelial dysfunction in human subjects, which is corrected completely by vitamin C administration suggesting a crucial role of reactive oxygen species (ROS) in mediating this phenomenon [17]. Recently, we have demonstrated that ISMN therapy causes endothelin-1 (ET-1) upregulation, NOX-2 activation, and eNOS uncoupling [18]. Very similar side effects, including augmented vascular ET-1 levels, were also reported for GTN therapy in animals [19, 20] and association of ET-1 mRNA with ISDN-induced tolerance in humans [21]. In contrast, other groups failed to observe upregulation of ET-1 in response to ISMN in vivo administration to rabbits [22] and were not able to prevent GTN-induced in vitro tolerance via the ET₁ receptor antagonist [23] and did not observe supersensitivity to the vasoconstrictor ET-1 in human internal mammary artery from patients with nitrate therapy [24] or in isolated bovine coronary arteries upon induction of GTN in vitro tolerance [25]. For the nitroxy anion donor Angeli’s salt, it was reported that it may overcome ET-1-induced vascular dysfunction in murine aorta, whereas GTN failed to show beneficial effects [26]. Previous findings on nitrate tolerance (mainly in response to GTN) with respect to activation of the endothelin-1 system and its interaction with oxidative stress are also summarized in several review articles [1, 2, 27]. Observations by others on GTN-induced activation of ROS formation in whole blood pointed towards a role of nitrates in white blood cell activation [28]. With our recent studies, we could demonstrate that phagocytic NADPH oxidase in circulating white blood cells is increased under chronic GTN and ISMN therapy [18, 29] and that the extent of ISMN-induced vascular complications is synergistically increased in the setting of type 1 diabetes mellitus and arterial hypertension [30, 31]. Others at least observed no beneficial effects of ISMN therapy on atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits [32]. Almost nothing is known about the mechanism of ISDN-induced side effects so far, and to our knowledge, no preclinical study has ever demonstrated that ISDN may cause endothelial dysfunction and whether this may be also linked to increased oxidative stress and increased endothelin expression.

The simultaneous upregulation of the vasoconstrictor ET-1 and increase in vascular oxidative stress can be best explained by the fact that ET-1 increases vascular superoxide formation via activation of the NADPH oxidase and stimulates inflammatory processes in mild hypertension models [33, 34]. Vice versa, it was also shown that NADPH oxidase-derived superoxide formation potentiates the vasoconstrictor properties of ET-1 [35] and that oxidative stress induces the ET-1 promoter and hence its expression [36, 37]. This provides the basis for a crosstalk or vicious circle for vasoconstrictor and oxidative stress pathways under organic nitrate therapy (reviewed in [2, 38]). In our own studies, we observed activation of leukocytes in response to ISMN in vivo therapy as well as in vitro challenges with ISMN, exogenous ET-1, or the ETₐ receptor agonist BQ-3020 [18, 39], which were blocked by bosentan cotherapy in selected experiments.

Chronic ISMN and ISDN therapy of mice is a suitable model to test the hypothesis of this crosstalk involving ET-1 and oxidative stress/inflammation in more detail. With the present study, we further elucidated the underlying mechanisms of the effects of ISMN and ISDN therapy on ET-1 signaling, NOX-2 activation, inflammation, and vascular dysfunction by cotreatment with the endothelin receptor antagonist macitentan, displaying slow apparent receptor association kinetics resulting in a significantly lower receptor dissociation rate and longer receptor occupancy half-life [40].

2. Materials and Methods

2.1. Reagents. Isosorbide dinitrate (ISDN; 50% (w/w) with 50% (w/w) lactose) was of analytical grade and obtained from Sigma-Aldrich or Fluka. Isosorbide-5-mononitrate (ISMN) was from LKT Laboratories (St. Paul, MN, USA). Macitentan (ACT-064992; N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yl oxy)ethoxy)pyrimidin-4-yl]-N’- propylaminosulfamide) was a kind gift of Actelion Pharmaceuticals Ltd. (Allschwil, Switzerland). For isometric tension studies, GTN was obtained from a Nitrolingual infusion solution (1 mg/ml) from G. Pohl-Boskamp (Hohenlockstedt, Germany). The Bradford reagent was obtained from Bio-Rad (Munich, Germany). All other chemicals were obtained from Fluka, Sigma-Aldrich, or Merck.

2.2. Cell Culture. RAW 264.7 cell macrophages were purchased from LGC Standards (Wesel, Germany). The cells were cultured in DMEM-NM (#21885-025) containing GlutaMAX from Life Technologies GmbH/Gibco (Darmstadt, Germany) with 10% fetal calf serum (FCS, PAA), penicillin (50 IU/ml), streptomycin (50 μg/ml), and 10% CO₂ as described [41]. Upon reaching confluence, the cells were split 1:3. For the final experiments, the cells were seeded into 96- or 6-well plates (final number of cells per well was 1 × 10⁶) and similar numbers of wells were incubated with medium alone (basal) or increasing concentrations of organic nitrates (GTN, ISMN, and ISDN) for 24 hours. The 96-well plates were used for ROS measurement by L-012-enhanced chemiluminescence analysis (100 μM) in...
PBS containing calcium and magnesium (1 mM). The 6-well plates were washed twice with PBS buffer, dried, and frozen in liquid nitrogen and stored at −80°C until dot blot analysis for the IL-6 content. A rabbit polyclonal antibody against IL-6 (1:5000, Abcam, Cambridge, UK) was used along with a secondary peroxidase-conjugated antibody against rabbit (1:10,000, Vector Lab., Burlingame, CA) as described [42]. Densitometric quantification of antibody-specific dots was performed with a ChemiLux Imager (CsX-1400 M, Intas, Göttingen, Germany) and the Gel-Pro Analyzer software (Media Cybernetics, Bethesda, MD).

2.3. Isolation of Leukocytes from Human Blood and Measurement of Oxidative Burst and Inflammation. Handling of all human material was in accordance with the Declaration of Helsinki and was approved by the local institutional Ethics Committee. Human whole blood from healthy volunteers was freshly collected in heparin-containing Monovettes (3 × 7.5 ml). Polymorphonuclear leucocytes (neutrophils, PMNs) were isolated by sedimentation of red blood cells with dextran and subsequent centrifugation on Ficoll as described previously [43]. Upon repeated hypotonic lysis of the cell pellet with pure water to eliminate the residual erythrocytes, total blood cell count and the purity of the PMN fraction were evaluated using an automated approach with a hematology analyzer KX-21N (Sysmex Europe GmbH, Norderstedt, Germany). The typical constitution of the blood cell fractions obtained by this method was previously reported by us [44]. The activation of PMN (10^4 cells/ml) was quantified by ROS formation during oxidative burst in response to a phorbol ester derivative (PDBu, 1 μM) using L-012-enhanced chemiluminescence (ECL) (100 μM) in PBS with 1 mM calcium/magnesium at 37°C on a Centro plate reader, using a 96-well plate, 200 μl sample per well, and the ECL signal (counts/s) at 20 min (Berthold Technology, Bad Wildbad, Germany).

Superoxide formation in stimulated PMN (10^6 cells/ml, 10 μM PDBu in PBS with 1 mM calcium/magnesium) was determined by incubation with 50 μM dihydroethidium (DHE) for 30 min at 37°C and quantification of the superoxide-specific oxidation product 2-hydroxyethidium (2-HE) by high-performance liquid chromatography (HPLC) as described [45]. 50 μl of the supernatant was subjected to HPLC analysis. The system consisted of a control unit, two pumps, mixer, detectors, column oven, degasser, and an autosampler (AS-2057 plus) from Jasco (Groß-Umstadt, Germany) and a C18-Nucleosil 100-3 (125 x 4) column from Macherey-Nagel (Düren, Germany). A high-pressure gradient was employed with 50 mM citrate buffer pH 2.2 (solvent A) and acetonitrile with 10% water (solvent B) as mobile phases with the following percentages of the organic solvent: 0 min, 40% B; 7 min, 45% B; 8–12 min, 100% B; 13 min, 40%. The flow was 1 ml/min, and DHE was detected by its absorbance at 355 nm, whereas 2-hydroxyethidium and ethidium were detected by fluorescence (Ex. 480 nm/Em. 580 nm). The effect of macitentan on ROS and superoxide formation was determined by coinubcation with increasing macitentan concentrations (1-1000 μM).

2.4. Animals and In Vivo Treatment. All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the US National Institutes of Health. All animal experimental protocols were reviewed by the Ethics Committee of the Johannes Gutenberg University Medical Center and approved by the Landesuntersuchungsamt (Koblenz, Germany; #23177-07/G 12-1-084 and G 14-1-028). All tissue preparations were performed according to established standards for the ethical treatment of animals. Male Wistar rats (8 weeks old, 350 g) were obtained from Charles River Laboratories (Sulzfeld, Germany) and were housed according to standard operating procedures in the animal facility of the Johannes Gutenberg University and were treated with ISDN (0, 10, 25, or 50 mg/kg/d) via administration in the drinking water for 7 days. Male C57BL/6j mice (10-12 weeks old, 25-30 g) were obtained from our own in-house animal facility and were housed according to standard operating procedures in the animal facility of the Johannes Gutenberg University. Mice were treated with ISMN (75 mg/kg/d) or ISDN (25 mg/kg/d) or the vehicle alone (dimethyl sulfoxide (DMSO)) via subcutaneous osmotic mini pumps (model 2007, ALZET, Cupertino, USA) for 7 days [31, 45]. All surgery was performed under ketamine/xylazine anesthesia (1 ml/kg of a ready to use solution containing 80 mg/ml ketamine and 12 mg/ml xylazine, Sigma-Aldrich). Control pumps were applied with the solvent (DMSO). For cotherapy, we used an oral dose of 30 mg/kg/d for the macitentan therapy (gavage, once daily) [46]. After one week of organic nitrate treatment with or without macitentan treatment, rats or mice were killed by exsanguination under isoflurane anesthesia, and the blood, aorta, and heart were collected.

2.5. Isometric Tension Recordings. The method was first described in [47]. Perivascular fat was removed from every thoracic aorta, and two ring segments (length 5-6 mm) were used for isometric tension studies of each mouse or rat. The ring segments were preconstricted by KCl in a concentration-dependent fashion (80 mM maximal concentration) in order to test the functional integrity of the tissue. Next, the ring segments were preconstricted by prostaglandin F2α (2-4 μM) for mice or phenylephrine (0.5-1 μM) for rats yielding a stable plateau constriction of 50-60% of the maximal KCl-dependent vasoconstriction. Concentration-relaxation curves in response to increasing concentrations of acetylcholine (ACh), ISMN, ISDN, or GTN were performed as described [18, 48, 49]. Concentration-constriction curves in response to increasing concentrations of ET-1 were performed with aortic rings without preconstriction as described [18].

2.6. Detection of Nitrosative Stress in Whole Blood by EPR Spectroscopy. Organic nitrate-derived NO levels in whole blood were measured using electron paramagnetic resonance (EPR) spectroscopy by nitrosyl-iron hemoglobin (HbNO) [50]. HbNO can be regarded as a read-out of nitrosative stress in whole blood as previously reported for GTN-induced tolerance in rats [51] or lipopolysaccharide-triggered endotoxemia in rats and mice [52]. Samples of...
venous blood were obtained by cardiac puncture of anesthetized rats; blood samples were snap frozen and later on stored in liquid nitrogen. The EPR measurements were carried out at 77 K using an X-band table-top spectrometer MS400 (Magnetech, Berlin, Germany). The instrument settings were as follows: 10 mW microwave power, 7000 mG amplitude modulation, 100 kHz modulation frequency, 3300 G center field, 300 G sweep width, 60 s sweep time, and 3 scans. HbNO levels were expressed as arbitrary units of intensity of the first peak of the characteristic triplet signal.

2.7. Dot Blot and Western Blot Analysis. The levels of 3-nitrotyrosine- (3-NT-) positive proteins and F4/80 expression were assessed by dot blot analysis [31, 53]. For detection of 3-NT, a primary mouse monoclonal nitrotyrosine antibody (Millipore, Billerica, USA) was used at a dilution of 1:1000. For imaging of F4/80, a primary rat monoclonal antibody (eBioscience, San Diego, CA, USA) was used at a dilution of 1:250. Detection and quantification were performed by ECL with peroxidase-conjugated secondary antibodies against mouse or rat (1:10,000, Vector Lab, Burlingame, CA). Densitometric quantification of antibody-specific dots was performed as described above.

Isolated aortic tissue from mice was frozen in liquid nitrogen and homogenized in buffer (Tris-HCl 20 mM, saccharose 250 mM, ethylene glycol-bis (β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) 3 mM, ethylene diamine tetraacetic acid (EDTA) 20 mM, protease inhibitor cocktail (Roche complete, 1 tablet in 100 ml), and Triton-X-100 1 v/v%). Proteins were separated by SDS-PAGE and blotted onto nitrocellulose membranes [18, 53]. After blocking, immunoblotting was performed with the following antibodies: polyclonal mouse β-actin (42 kDa) and α-actinin (100 kDa) as a control for loading and transfer (both from Sigma-Aldrich, USA), monoclonal mouse NADPH oxidase 2 (NOX-2, 1:500, BD Bioscience, USA), and polyclonal rabbit ETB receptor (ETB, 1:5000, Abcam, USA). Detection and quantification were performed by ECL with peroxidase-conjugated secondary antibodies against mouse or rabbit (1:10,000, Vector Lab., Burlingame, CA). Densitometric quantification was performed as described above.

2.8. Immunohistochemical (IHC) Analysis of ET-1 Expression. Aortic samples were fixed in paraformaldehyde (4%), embedded in paraffin, and stained with a primary mouse antibody against ET-1 (Pierce #MA3-005: 1:200). Biotinylated secondary antibody (anti-mouse included in M.O.M. Kit, Vector Lab., Burlingame) was used at a dilution according to the manufacturer’s instructions. For immunohistochemical detection, ABC reagent (Vector) and then DAB reagent (peroxidase substrate kit, Vector) were used as substrates.
NADPH oxidase activity in the Heart and Aorta. 2.9. Assessment of Oxidative Stress and NADPH Oxidase Activity in the Heart and Aorta. NADPH oxidase activity in membrane fractions of heart tissue was determined by lucigenin (5 µM) ECL in the presence of 200 µM NADPH [42, 43]. For ROS formation in aortic tissue, isolated aortic ring segments were OCT-embedded (Tissue-Tek, USA), and upon staining with dihydroethidium (DHE, 1 µM), oxidative fluorescence microtopography was determined as reported [53, 54].

2.10. Reverse Transcription Real-Time PCR (qRT-PCR). mRNA expression was analyzed with quantitative real-time RT-PCR as previously described [41, 42, 54]. Briefly, total RNA from the mouse aorta or heart was isolated (RNeasy Fibrous Tissue Mini Kit; Qiagen, Hilden, Germany), and 50 ng of total RNA was used for real-time RT-PCR analysis with the QuantiTectTM Probe RT-PCR kit (Qiagen). TaqMan® Gene Expression assays for NADPH oxidase isoform 2 (NOX-2), endothelin-1b receptor (ETbR), endothelin-converting enzyme-1 (ECE-1), monocyte chemotactic protein-1 (MCP-1), CD11b, interleukin-6 (IL-6), and TATA box-binding protein (TBP) were purchased as probe and primer sets (Applied Biosystems, Foster City, CA). The comparative Ct method was used for relative mRNA quantification. Gene expression was normalized to the endogenous control (TBP mRNA), and the amount of target gene mRNA expression in each sample was expressed relative to that of control.

2.11. Statistical Analysis. Results are expressed as mean ± SEM. Two-way ANOVA (with Bonferroni’s correction for comparison of multiple means) was used for comparisons of vasodilator potency and efficacy. One-way ANOVA (with Bonferroni’s or Dunn’s correction for comparison of multiple means) was used for comparisons of all other parameters. p values < 0.05 were considered as statistically significant.

3. Results

3.1. Studies with Cultured and Isolated Immune Cells. In cultured RAW 264.7 cell macrophages, GTN, ISDN, and ISMN increased the oxidative burst signal in these macrophages upon phorbol ester stimulation (Figures 1(a)–1(c)). Suprapharmacological concentrations of ISDN and ISMN suppressed the ROS signal (Figures 1(b) and 1(c)), likely due to the release of NO quenching the superoxide anions. Accordingly, we established higher protein tyrosine nitration levels at higher concentrations of GTN (Figure 1(d)). All organic nitrates increased the IL-6 expression in these macrophages, at least at one specific concentration (Figures 1(e)–1(g)). The endothelin receptor blocker macitentan suppressed the superoxide signal in phorbol ester-stimulated human granulocytes (PMN) (Figure 2), indicating a role of endothelin signaling in this process.

3.2. Pilot Study for ISDN in Rats. Since we had no previous expertise on ISDN in vivo treatment of animals, we performed a dose-response study in rats. ISDN was administered at increasing doses in the drinking water. The ISDN dose of 25 and 50 mg/kg/d induced no significant endothelial dysfunction, although a trend of impaired acetylcholine-dependent relaxation was visible (Figure 3(a)). In contrast, the ISDN-dependent relaxation was significantly impaired in response to 25 and 50 mg/kg/d of ISDN (and the 10 mg/kg/d in one point of the concentration-relaxation curve) indicating a mild nitrate tolerance for the higher doses of ISDN (Figure 3(b)). Treatment with ISDN at 25 mg/kg/d also caused supersensitivity to the vasoconstrictor ET-1 (Figure 3(c)). Successful uptake of the drug in an effective
dose was tested by measurement of nitrosyl-iron hemoglobin (HbNO), a marker of whole blood nitrosative stress due to high levels of NO-derived nitrosating species as previously reported by us in endotoxin-induced sepsis or GTN-induced nitrate tolerance. ISDN treatment dose dependently increased the HbNO levels in whole blood of rats proving the successful delivery of the drug at all doses (Figure 3(d)). Based on our previous experience on successful s.c. administration of ISMN to mice via osmotic mini pumps and the present findings on lack of endothelial dysfunction in orally ISDN-treated rats, we decided to use the s.c. protocol for ISMN and ISDN administration in our mouse model. Successful uptake of ISMN (75 mg/kg/d) and ISDN (25 mg/kg/d) in effective doses was tested by measurement of nitrosyl-iron hemoglobin (HbNO). Both organic nitrates induced a clearly detectable HbNO signal, which was almost 2-fold higher in the ISMN group (Figure 3(e)). Macitentan reduced the nitrosative stress signal in both groups by approximately 50%, at least by trend.

3.3. ISMN In Vivo Treatment

3.3.1. Vascular Function and Cardiovascular Oxidative Stress Parameters in the Mouse Aorta. ISMN treatment caused endothelial dysfunction but no appreciable tolerance to ISMN and no cross-tolerance to GTN (Figures 4(a)–4(c)). Endothelial dysfunction was improved by macitentan cotherapy (Figure 4(a)). The sensitivity of the vasculature to prostaglandin F2α-dependent constriction was neither affected by ISMN treatment nor by macitentan cotherapy.
ISMN increased aortic ROS production that was corrected by macitentan cotherapy (Figure 5(a)). Cardiac protein tyrosine nitration, as a marker for in vivo peroxynitrite formation, was increased by ISMN therapy and normalized by macitentan (Figure 5(b)). Cardiac NADPH oxidase activity was increased in response to ISMN and normalized by macitentan (Figure 5(c)). However, these oxidative stress parameters were somewhat more efficiently normalized in cardiac tissue as compared to aortic tissue, suggesting the contribution of different ROS sources to ISMN-mediated oxidative damage in these tissues.

3.3.2. Protein and mRNA Expression. Aortic NOX-2 protein expression was increased by ISMN treatment and significantly decreased by macitentan (Figures 6(a) and 6(c)). The expression pattern was almost similar at the mRNA level (Figure 7(a)). The protein expression of the ET_B receptor was not modified (Figure 6(b)–6(c)). Inflammatory markers were increased at the protein level in the aorta of ISMN-treated mice as envisaged by higher F4/80 expression (Figure 6(d)) but also at the mRNA expression levels of MCP-1 and CD11b (Figures 7(b)–7(c)), all of which were mostly normalized by macitentan cotherapy.

(Figure 4(d)). ISMN increased aortic ROS production that was corrected by macitentan cotherapy (Figure 5(a)). Cardiac protein tyrosine nitration, as a marker for in vivo peroxynitrite formation, was increased by ISMN therapy and normalized by macitentan (Figure 5(b)). Cardiac NADPH oxidase activity was increased in response to ISMN and normalized by macitentan (Figure 5(c)). However, these oxidative stress parameters were somewhat more efficiently normalized in cardiac tissue as compared to aortic tissue, suggesting the contribution of different ROS sources to ISMN-mediated oxidative damage in these tissues.

3.3.2. Protein and mRNA Expression. Aortic NOX-2 protein expression was increased by ISMN treatment and significantly decreased by macitentan (Figures 6(a) and 6(c)). The expression pattern was almost similar at the mRNA level (Figure 7(a)). The protein expression of the ET_B receptor was not modified (Figure 6(b)–6(c)). Inflammatory markers were increased at the protein level in the aorta of ISMN-treated mice as envisaged by higher F4/80 expression (Figure 6(d)) but also at the mRNA expression levels of MCP-1 and CD11b (Figures 7(b)–7(c)), all of which were mostly normalized by macitentan cotherapy.
ET-1 protein expression was envisaged by immunohistochemistry and was more pronounced in the ISMN groups (Figure 6(e)). The mRNA expression of the endothelin-converting enzyme-1 (ECE-1) showed no significant changes (Figure 7(d)).

3.4. ISDN In Vivo Treatment

3.4.1. Vascular Function and Cardiovascular Oxidative Stress Parameters in the Mouse Aorta. ISDN treatment caused endothelial dysfunction but no pronounced tolerance to ISDN and cross-tolerance to GTN (Figures 8(a)–8(c)). Endothelial dysfunction was significantly improved by macitentan cotherapy (Figure 8(a)). The prostaglandin F₂α-dependent constriction was neither affected by ISDN treatment nor by macitentan cotherapy (not shown). Aortic ROS formation was significantly augmented in response to ISDN and normalized by macitentan (Figure 8(d)).

3.4.2. mRNA Expression. The mRNA expression of Nox2 was not increased by ISDN infusion but showed a robust decrease by macitentan cotherapy (Figure 9(a)). The mRNA expression of ECE-1 showed a trend of an increase under ISDN therapy and a complete normalization by cotherapy with macitentan (Figure 9(b)). The mRNA expression of the marker of inflammation, MCP-1, was increased by ISDN infusion and normalized by cotherapy with macitentan (Figure 9(c)). The mRNA level of the cytokine IL-6 was increased by ISDN infusion and normalized by cotherapy with macitentan (Figure 9(d)). Immunohistochemical staining for ET-1 revealed a minor increase in the ISDN group and a moderate decrease by macitentan therapy (Figure 9(e)).

4. Discussion

The results of the present study demonstrate that the organic nitrates ISMN and ISDN cause an increase in whole blood nitrosative stress and vascular/cardiac oxidative stress, activate ET receptor signaling pathways, and induce an inflammatory phenotype of the vascular system leading to endothelial dysfunction. By using the dual ET receptor blocker macitentan, we were able to avoid these major cardiovascular side effects of the organic nitrate therapy (although oxidative stress parameters per se were somewhat more efficiently normalized in the heart as compared to the aorta pointing towards different ROS sources that are activated by ISMN treatment in these tissues), further supporting a key role of ET receptor signaling in these ISMN/ISDN-induced side effects. The novel aspects of the present studies, besides the evaluation of the protective effects of the dual ET receptor blocker macitentan in the setting of nitrate tolerance, are mainly based on the identification of increased ET-1 expression, supersensitivity to ET-1-dependent vasoconstriction, followed by adverse ET receptor signaling, increased oxidative stress, inflammation, and vascular dysfunction in ISDN-treated animals. ISDN-induced endothelial dysfunction was shown in humans before but without providing a mechanistic explanation [55].

Previous studies by our group and others demonstrated that GTN and ISMN therapy upregulates ET-1 expression in the vessels of animals [18–20]. The only organic nitrate
so far that is devoid of the primary clinical side effects of nitrate therapy (e.g., oxidative stress and nitrate tolerance) is pentaerythritol tetranitrate (PETN) [1, 27]. This was demonstrated in healthy subjects [56], patients with pulmonary arterial hypertension [57], in patients with chronic stable angina [58], in women with preeclampsia [59], or in experimental models such as type 1 diabetes mellitus, arterial hypertension, and pulmonary hypertension [30, 31, 39, 60] as well as congestive heart failure [61, 62]. PETN treatment leads to an induction of the highly protective enzymes heme oxygenase-1 (HO-1), ferritin [63–66], glutathione peroxidase [60], and superoxide dismutase with recoupling of eNOS [67] leading to improved mobilization of endothelial progenitor cells [68]. These protective effects of PETN are not shared by GTN, ISMN, or ISDN and require the transcription factor Nrf-2 [30, 69] and are absent in HO-1 knockout mice [31]. Thus, PETN induces gene expression of antioxidant enzymes, a property not shared by GTN [70] and likely mediated by beneficial epigenetic changes [71].

In rats with pulmonary hypertension, we recently demonstrated that PETN interferes with ET-1 signaling (downregulation of ET-1, ECE-1, and ET_A and ET_B receptor mRNA expression), thereby improving cardiac and vascular function and reducing cardiovascular and pulmonary oxidative stress and inflammation [39]. Furthermore, PETN suppressed the oxidative burst induced by the ET receptor agonist BQ-3020 in whole blood leukocytes and normalized adhesion molecule (ICAM-1) mRNA expression in cultured endothelial cells (EA.hy926). These data further highlight a key role of ET receptor signaling for the adverse effects of organic nitrates and emphasize the potential benefits of treating patients with ISMN, ISDN, or GTN in combination with ET receptor blockers such as macitentan. In contrast, ET receptor blocker cotherapy will likely not further improve the clinical benefits of PETN therapy, since this organic nitrate is already devoid of most clinical side effects such as nitrate tolerance, endothelial dysfunction, and oxidative stress due to induction of intrinsic protective pathways [27, 72–74] and suppression of the ET receptor signaling pathway [39].

So far, it is not completely understood how ET-1 increases vascular superoxide formation. ET-1 activates NADPH oxidase and causes inflammation in hypertensive animals [33, 34] and, vice versa, NADPH oxidase-derived superoxide formation increases ET-1-mediated vasoconstriction [35], most likely mediated by oxidative stress-induced preproET-1 gene promoter activation [36, 37]. GTN therapy also activates protein kinase C (PKC) [19] and increased PKC activity induces the expression of the ET_B receptor [75]. PKC is also required for the activation of the NADPH oxidase isoforms NOX-1 and NOX-2. Further, ET-1 triggers PKC-dependent eNOS uncoupling and subsequent endothelial

**Figure 6:** Characterization of vascular protein expression within the inflammatory and ET receptor signaling pathways and protective effects of macitentan cotherapy in ISMN-treated mice. The vascular protein expression of NOX-2 (a) and ET_B receptor (b) was determined by western blot analysis. Representative blots are shown besides the densitometric quantification (c). The vascular protein expression of F4/80 was determined by dot blot analysis (d). Representative dot blots are shown besides the densitometric quantification. Immunohistochemical staining for ET-1 in aortic paraffin sections (e). Arrows indicate ET-1-specific brown color. Representative images for 4 independent experiments. The data are mean ± SEM from 5-6 (a), 5-6 (b), and 4-7 (c) mice per group. *p < 0.05 vs. control; #p < 0.05 vs. ISMN group.
dysfunction; all of which was improved by bosentan therapy [76]. Thus, the NADPH oxidase pathway, especially the NOX-2 isoform, and ET-1 signaling are interconnected and can stimulate each other, leading to a vicious circle in the NOX-2/ET receptor signaling axis (for review, see [2, 38]). Activation of PKC by organic nitrates and ET-1 may even become more important in a broader context since PKC is a major regulator of dendritic cell activation and maturation playing a central role in adaptive immune responses by antigen processing and (cross-)activation of T cells [77].

NOX-2 in immune and vascular cells represents an important source of ROS, which play a major role in the pathogenesis of cardiovascular disease in general and nitrate-induced tolerance and endothelial dysfunction in particular. NOX-2 can be activated in a redox regulatory fashion by mitochondrial ROS formation as shown for GTN-induced nitrate tolerance and endothelial dysfunction [45] as well as angiotensin II-induced hypertension and the aging process [53, 78]. We therefore assessed NOX-2 expression and NOX activity as well as different markers of vascular/cardiac oxidative stress. Elevated superoxide levels react with eNOS-derived \( \cdot \text{NO} \) to ONOO\(^{-} \) [79], which reduces NO bioavailability and thereby contributes to endothelial dysfunction. We assessed nitrooxidative stress levels in cardiac tissue of ISMN-treated mice by 3-NT-positive protein content reflecting increased peroxynitrite (ONOO\(^{-} \)) formation and ROS formation in vessels of ISMN- and ISDN-treated mice by DHE fluorescence microtopography. Both oxidative stress parameters were clearly increased in organic nitrate-treated animals and normalized by macitentan cotherapy. Since the effect of macitentan on ISMN-dependent NOX-2 activation and expression was quite pronounced and went in parallel with its anti-inflammatory effects, we propose a key role for NOX-2 in the observed adverse vascular effects of ISMN (and probably also ISDN) therapy. However, since the inhibition of NOX-2 activity/expression by macitentan was even more pronounced than suppression of oxidative stress parameters by ET receptor blockade, we cannot exclude that also other ROS sources (e.g., mitochondria, NOX-1, or NOX-4) contribute to the overall oxidative stress condition induced by ISMN or ISDN therapy. The contribution of different ROS sources in the aorta and the heart may also explain why the effect of macitentan treatment on oxidative stress parameters in these tissues is not always comparable.

**Figure 7:** Characterization of vascular mRNA expression within the inflammatory and ET receptor signaling pathways and protective effects of macitentan cotherapy in ISMN-treated mice. qRT-PCR was used to determine mRNA expression levels of Nox-2 (a), MCP-1 (b), CD11b (c), and ECE-1 (d). The data are mean ± SEM from 9-10 (a), 8-9 (b), 6-7 (c), and 8-9 (d) mice per group. \(* p < 0.05\) vs. control; \(# p < 0.05\) vs. ISMN group.
We also provide evidence for excessive NO generation by ISDN/ISMN in the blood (reflected by increased HbNO levels = nitrosative stress), which was previously also reported for GTN treatment [80]. Recently, we showed that aortic NO bioavailability can be decreased in GTN-treated rats [81] despite a substantial increase in NO-associated nitrosyl-iron hemoglobin (HbNO) in whole blood of these rats [51]. Accordingly, the observed partial normalization of HbNO levels in ISMN- and ISDN-treated mice by macitentan may be interpreted as a beneficial effect of the ET receptor blocker.

It is well known that organic nitrates activate immune cells and stimulate immune cell-dependent ROS formation. In our own previous studies, we established that GTN dose dependently increased the oxidative burst signals in whole blood [51] and that treatment with the AT1 receptor blocker telmisartan effectively suppressed this burst. [29]. In addition, in vivo treatment with GTN decreased the activity
of the redox-sensitive enzyme mitochondrial aldehyde dehydrogenase (ALDH-2) in isolated white blood cells of GTN-treated human volunteers and rats [44] and increased whole blood free radicals [28], compatible with immune cell activation and altered redox status in these cells in response to therapy with the organic nitrate. ISMN in vivo therapy as well as in vitro challenges with ISMN, authentic ET-1, or the ET-1A receptor agonist BQ-3020 caused leukocyte activation [18, 39], which was blocked by bosentan cotherapy in selected experiments.

ISMN, ISDN, and GTN stimulated the oxidative burst and release of cytokine IL-6 by cultured macrophages, and macitentan suppressed the oxidative burst signal in isolated human leukocytes. These data, together with the above mentioned inflammatory properties of ET-1 [33, 34], provide a direct link between ET receptor signaling, the onset of inflammation, and oxidative stress in response to organic nitrate therapy, further supporting the above postulated vicious circle in the NOX-2/ET receptor signaling axis.

An important observation of the present studies was that ISDN is causing endothelial dysfunction that is clearly linked to oxidative stress and activation of the ET-1 vasoconstrictor pathway. Interestingly, the combination of ISDN and hydralazine has been shown to have strong beneficial and long-lasting hemodynamic effects and has also been demonstrated to improve prognosis of chronic congestive heart failure patients [82, 83], likely because of the improvement of the nitroso-redox balance [84]. Since we demonstrated that hydralazine is a strong peroxynitrite quencher in GTN-induced vascular dysfunction [85, 86], it is reasonable to conclude that ISDN and hydralazine are not only working synergistically together from the hemodynamic point of view but also that the antioxidant properties of hydralazine may come into play, thus preventing ISDN-induced vascular dysfunction and proinflammatory effects by its antioxidant properties.

5. Conclusions

We demonstrated here for the first time that endothelial dysfunction induced by ISDN is linked to increased oxidative stress and endothelin-1 induction in vascular tissue providing...
a mechanistic explanation for the previously described ISDN-induced endothelial dysfunction in humans [55]. Treatment with the endothelin receptor blocker macitentan prevented endothelial dysfunction (ACh response), vascular/cardiac oxidative stress (DHE staining, 3-NT, lucigenin ECL), activation of the endothelin receptor signaling pathway, and an inflammatory phenotype of the vasculature induced by ISMN and ISDN therapy (Figure 10). Thus, our present data identified a vicious circle of the NOX-2/ET receptor signaling axis caused by ISMN/ISDN leading to augmented NOX-2 activity and ET receptor signaling. Of note, ROS and ET-1 signaling are also potent triggers of vascular inflammation (for review, see [38, 89]). Accordingly, ET receptor blockade by macitentan successfully blocks white blood cell (WBC) activation and infiltration, oxidative tissue damage, and endothelial dysfunction. The scheme was modified from [90] with permission of the publisher. Copyright © 2012, Oxford University Press.

confirm the unique properties of PETN as a clinical nitrovasodilator drug that causes induction of intrinsic antioxidant/protective pathways [27, 72, 73] and suppression of ET receptor signaling [39], emphasizing that organic nitrates are not a homogenous class of drugs [74].

**Abbreviations**

3-NT: 3-Nitrotyrosine  
ACh: Acetylcholine  
DHE: Dihydroethidium  
eNOS: Endothelial nitric oxide synthase  
ECE-1: Endothelin-converting enzyme-1  
EPR: Electron paramagnetic resonance  
ET: Endothelin  
ET-1: Endothelin-1  
ETα receptor: Endothelin receptor type A  
ETβ receptor: Endothelin receptor type B  
GTN: Nitroglycerin  
HbNO: Nitrosyl-iron hemoglobin  
IL-6: Interleukin-6  
ISDN: Isosorbide dinitrate  
ISMN: Isosorbide-5-mononitrate
Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure

The work contains parts of the thesis of Siyer Roohani. Part of the data in the present manuscript were presented as a poster and oral short presentation at the congress of the European Society of Cardiology (ESC) 2017 in Barcelona (Spain) and at the annual meeting of the German Cardiac Society (DGK) 2017 in Mannheim (Germany). The conference abstracts were published in *Eur. Heart J.* 2017; 38 (S1):ehx504.P3470 and in *Clin. Res. Cardiol.* 2017;106 (S1):V43 - DOI 10.1007/s00392-017-1105-2.

Conflicts of Interest

Andreas Daiber and Thomas Münzel received research grant support from Actelion Pharmaceuticals Deutschland GmbH (Freiburg im Breisgau, Germany). Christine Baum is an employee of Actelion Pharmaceuticals Deutschland GmbH (Freiburg im Breisgau, Germany). Marc Iglarz is an employee of Actelion Pharmaceuticals Ltd. (Allschwil, Switzerland). All other authors have no competing interests.

Authors’ Contributions

S.S. and A.D. conceived and designed the research; S.S., M.O., M.H., S.R., F.K., S.K.-S., J.H., and T.J. carried out the experiments; C.B. and M.I. contributed with the analytic tools; S.S., M.O., M.H., and A.D. performed the data analysis; S.S. and A.D. drafted the manuscript. E.S. and T.M. made critical contribution to the discussion. M.O., C.B., M.I., E.S., and T.M. revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We are indebted to Angelica Karpi, Jörg Schreiner, Nicole Glas, Jessica Rudolph, and Bettina Mros for expert technical assistance. The present work was supported by a vascular biology research grant from Actelion Pharmaceuticals Deutschland GmbH, Freiburg im Breisgau (A.D. and T.M.), financial support by the Foundation Mainzer Herz (A.D. and T.M.), and the German Heart Foundation/German Foundation of Heart Research (F/42/13 to S.S.). Sebastian Steven holds a Virchow Fellowship from the Center of Thrombosis and Hemostasis (Mainz, Germany) funded by the Federal Ministry of Education and Research (BMBF 01EO1003 to S.S., and TRP3 to A.D.). Siyer Roohani and Fatemeh Kashani were supported by an MD thesis stipend from the Robert Müller Foundation (Mainz, Germany).

References

[1] T. Munzel, A. Daiber, and T. Gori, “Nitrate therapy: new aspects concerning molecular action and tolerance,” *Circulation*, vol. 123, no. 19, pp. 2132–2144, 2011.
[2] T. Munzel, A. Daiber, and T. Gori, “More answers to the still unresolved question of nitrate tolerance,” *European Heart Journal*, vol. 34, no. 34, pp. 2666–2673, 2013.
[3] T. Gori and J. D. Parker, “Long-term therapy with organic nitrates: the pros and cons of nitric oxide replacement therapy,” *Journal of the American College of Cardiology*, vol. 44, no. 3, pp. 632–634, 2004.
[4] A. Daiber, P. Wenzel, M. Oelze, and T. Munzel, “New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance,” *Clinical Research in Cardiology*, vol. 97, no. 1, pp. 12–20, 2008.
[5] T. Munzel, A. Daiber, and A. Mulisch, “Explaining the phenomenon of nitrate tolerance,” *Circulation Research*, vol. 97, no. 7, pp. 618–628, 2005.
[6] T. Gori and J. D. Parker, “Nitrate tolerance: a unifying hypothesis,” *Circulation*, vol. 106, no. 19, pp. 2510–2513, 2002.
[7] T. Gori, J. S. Floras, and J. D. Parker, “Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans,” *Journal of the American College of Cardiology*, vol. 40, no. 11, pp. 2000–2005, 2002.
[8] U. Jurt, T. Gori, A. Ravandi, S. Babaei, P. Zeman, and J. D. Parker, “Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study,” *Journal of the American College of Cardiology*, vol. 38, no. 3, pp. 853–859, 2001.
[9] K. Sydow, A. Daiber, M. Oelze et al., “Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance,” *The Journal of Clinical Investigation*, vol. 113, no. 3, pp. 482–489, 2004.
[10] Z. Chen, J. Zhang, and J. S. Stamler, “Identification of the enzymatic mechanism of nitroglycerin bioactivation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 12, pp. 8306–8311, 2002.
[11] S. Lin, N. A. Page, S. M. Fung, and H. L. Fung, “In vitro organic nitrate bioactivation to nitric oxide by recombinant aldehyde dehydrogenase 3A1,” *Nitric Oxide*, vol. 35, pp. 137–143, 2013.
[12] P. S. Tsou, N. A. Page, S. G. Lee, S. M. Fung, W. M. Keung, and H. L. Fung, “Differential metabolism of organic nitrates by aldehyde dehydrogenase 1a1 and 2: substrate selectivity, enzyme inactivation, and active cysteine sites,” *The AAPS Journal*, vol. 13, no. 4, pp. 548–555, 2011.
[13] M. Beretta, G. Wolkart, M. Schernthaner et al., “Vascular bioactivation of nitroglycerin is catalyzed by cytosolic aldehyde dehydrogenase-2,” *Circulation Research*, vol. 110, no. 3, pp. 385–393, 2012.
[14] Y. Minamiyama, S. Takemura, T. Akiyama et al., “Isoforms of cytochrome P 450 on organic nitrate-derived nitric oxide release in human heart vessels,” *FEBS Letters*, vol. 452, no. 3, pp. 165–169, 1999.
[15] Y. Minamiyama, S. Takemura, S. Imaoka, Y. Funae, and S. Okada, “Cytochrome P 450 is responsible for nitric oxide generation from NO-aspirin and other organic nitrates,” Drug Metabolism and Pharmacokinetics, vol. 22, no. 1, pp. 15–19, 2007.

[16] J. J. Doel, B. L. J. Godber, R. Eisenthal, and R. Harrison, “Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions,” Biochimica et Biophysica Acta, vol. 1527, no. 1–2, pp. 81–87, 2001.

[17] G. R. Thomas, J. M. DiFabio, T. Gori, and J. D. Parker, “Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism,” Journal of the American College of Cardiology, vol. 49, no. 12, pp. 1289–1295, 2007.

[18] M. Oelze, M. Knorr, S. Kroller-Schon et al., “Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression,” European Heart Journal, vol. 34, no. 41, pp. 3206–3216, 2013.

[19] T. Munzel, A. Giaid, S. Kurz, D. J. Stewart, and D. G. Harrison, “Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance,” Proceedings of the National Academy of Sciences, vol. 92, no. 11, pp. 5244–5248, 1995.

[20] J. D. Ratz, A. B. Fraser, K. J. Rees-Milton, M. A. Adams, and B. M. Bennett, “Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrate tolerance in the rat,” The Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 2, pp. 578–585, 2000.

[21] J. Wang, S. D. Wu, S. C. Chen et al., “Effect of compound salvia injection on nitrate ester tolerance,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 25, no. 1, pp. 25–29, 2005.

[22] L. Chen, J. Q. Jiang, Y. Zhang, and H. Feng, “Experimental study on oral sulphhydryl as an adjuvant for improving nitrate ester tolerance in an animal model,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 5, pp. 1469–1477, 2018.

[23] C. Q. Liu, F. P. Leung, W. Y. Y. Lee et al., “Prevention of nitroglycerin tolerance in vitro by T 0156, a selective phosphodiesterase type 5 inhibitor,” European Journal of Pharmacology, vol. 590, no. 1–3, pp. 250–254, 2008.

[24] K. E. Wiley and A. P. Davenport, “Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro,” Clinical Science, vol. 103, no. s2002, pp. 124S–127S, 2002.

[25] C. L. Zhang, I. S. Lande, and J. D. Horowitz, “Effects of glyceryl trinitrate tolerance on vascular responsiveness to constrictor agents in bovine isolated coronary artery,” Clinical and Experimental Pharmacology & Physiology, vol. 22, no. 5, pp. 324–329, 1995.

[26] B. M. Wynne, H. Labazi, Z. N. Carneiro, R. C. Tostes, and R. C. Webb, “Angeli’s salt, a nitroxyl anion donor, reverses endothelin-1-mediated vascular dysfunction in murine aorta,” European Journal of Pharmacology, vol. 814, pp. 294–301, 2017.

[27] A. Daiber and T. Munzel, “Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: emphasis on redox biology and oxidative stress,” Antioxidants & Redox Signaling, vol. 23, no. 11, pp. 899–942, 2015.

[28] M. Schwemmer and E. Basset, “New approaches to overcome tolerance to nitrates,” Cardiovascular Drugs and Therapy, vol. 17, no. 2, pp. 159–173, 2003.

[29] M. Knorr, M. Hausding, S. Kroller-Schuhmacher et al., “Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and s-gluthationylation of endothelial nitric oxide synthase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2223–2231, 2011.

[30] S. Schuhmacher, M. Oelze, F. Bollmann et al., “Vascular dysfunction in experimental diabetes is improved by pentaethrityl tetranitrate but not isosorbide-5-mononitrate therapy,” Diabetes, vol. 60, no. 10, pp. 2608–2616, 2011.

[31] S. Schuhmacher, P. Wenzel, E. Schulz et al., “Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1,” Hypertension, vol. 55, no. 4, pp. 897–904, 2010.

[32] G. Kojda, D. Stein, E. Kottenberg, E. M. Schnaith, and E. Noack, “In vivo effects of pentaethyritol-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits,” Journal of Cardiovascular Pharmacology, vol. 25, no. 5, pp. 763–773, 1995.

[33] L. Li, G. D. Fink, S. W. Watts et al., “Endothelin-1 increases vascular superoxide via endothelin (A)-NADPH oxidase pathway in low-renin hypertension,” Circulation, vol. 107, no. 7, pp. 1053–1058, 2003.

[34] L. Li, Y. Chu, G. D. Fink, J. F. Engelhardt, D. D. Heistad, and A. F. Chen, “Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension,” Hypertension, vol. 42, no. 5, pp. 997–1003, 2003.

[35] L. Li, S. W. Watts, A. K. Banes, J. J. Galligan, G. D. Fink, and A. F. Chen, “NADPH oxidase-derived superoxide augments endothelin-1-induced vеноconstriction in mineralocorticoid hypertension,” Hypertension, vol. 42, no. 3, pp. 316–321, 2003.

[36] J. Kahler, A. Ewert, J. Weckmuller et al., “Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells,” Journal of Cardiovascular Pharmacology, vol. 38, no. 1, pp. 49–57, 2001.

[37] J. Kahler, S. Mendel, J. Weckmuller et al., “Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 8, pp. 1429–1437, 2000.

[38] A. Daiber, F. Di Lisa, M. Oelze et al., “Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function,” British Journal of Pharmacology, vol. 174, no. 12, pp. 1670–1689, 2017.

[39] S. Steven, M. Oelze, M. Brandt et al., “Pentaerythritol tetranitrate in vivo treatment improves oxidative stress and vascular dysfunction by suppression of endothelin-1 signaling in monocrotaline-induced pulmonary hypertension,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 4353462, 13 pages, 2017.

[40] J. Gatfield, C. Mueller Grandjean, T. Sasse, M. Clozel, and O. Nayler, “Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells,” PLoS One, vol. 7, no. 10, article e47662, 2012.

[41] M. Hausding, K. Jurk, S. Daub et al., “CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction,” Basic Research in Cardiology, vol. 108, no. 6, p. 386, 2013.

[42] S. Steven, M. Dib, M. Hausding et al., “CD40L controls obesity-associated vascular inflammation, oxidative stress,
and endothelial dysfunction in high fat diet-treated and db/db mice,” Cardiovascular Research, vol. 114, no. 2, pp. 312–323, 2018.

[43] A. Daiber, M. August, S. Baldus et al., “Measurement of NAD (P)H oxidase-derived superoxide with the luminol analogue L-012,” Free Radical Biology & Medicine, vol. 36, no. 1, pp. 101–111, 2004.

[44] P. Wenzel, E. Schulz, T. Gori et al., “Monitoring white blood cell mitochondrial aldehyde dehydrogenase activity: implications for nitrate therapy in humans,” The Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 1, pp. 63–71, 2009.

[45] P. Wenzel, H. Mollau, M. Oelze et al., “First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction,” Antioxidants & Redox Signaling, vol. 10, no. 8, pp. 1435–1448, 2008.

[46] M. Iglarz, C. Binkert, K. Morrison et al., “Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist,” The Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 3, pp. 736–745, 2008.

[47] T. Münzel, H. Sayegh, B. A. Freeman, M. M. Tarpey, and D. G. Harrison, “Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underly-
ing tolerance and cross-tolerance,” Journal of Clinical Investigation, vol. 95, no. 1, pp. 187–194, 1995.

[48] P. Wenzel, U. Hink, M. Oelze et al., “Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2−/− mice,” British Journal of Pharmacology, vol. 150, no. 4, pp. 526–533, 2007.

[49] A. L. Kleschyov, M. Oelze, A. Daiber et al., “Does nitric oxide mediate the vasodilator activity of nitroglycerin?,” Circulation Research, vol. 93, no. 9, pp. e104–e112, 2003.

[50] M. Oelze, A. Daiber, R. P. Brandes et al., “Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats,” Hypertension, vol. 48, no. 4, pp. 677–684, 2006.

[51] Y. Mikhed, J. Fahrer, M. Oelze et al., “Nitroglycerin induces DNA damage and vascular cell death in the setting of nitrate tolerance,” Basic Research in Cardiology, vol. 111, no. 4, p. 52, 2016.

[52] S. Steven, M. Hausding, S. Kroller-Schon et al., “Glipitin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia,” Basic Research in Cardiology, vol. 110, no. 2, p. 6, 2015.

[53] M. Oelze, S. Kroller-Schon, S. Steven et al., “Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging,” Hypertension, vol. 63, no. 2, pp. 390–396, 2014.

[54] S. Steven, M. Oelze, A. Hanf et al., “The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats,” Redox Biology, vol. 13, pp. 370–385, 2017.

[55] M. Sekiya, M. Sato, J. Funada, T. Ohtani, H. Akutsu, and K. Watanabe, “Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis,” Journal of Cardiovascular Pharmacology, vol. 46, no. 1, pp. 63–67, 2005.

[56] T. Gori, A. Al-Hesayen, C. Jolliffe, and J. D. Parker, “Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers,” The American Journal of Cardiology, vol. 91, no. 11, pp. 1392–1394, 2003.

[57] H.-G. Predel, H. Knigge, U. Prinz, H. J. Kramer, D. Stalleicken, and R. E. Rost, “Exercise increases endothelin-1 plasma concentrations in patients with coronary artery disease: modulatory role of LDL cholesterol and of pentaerithritoltetranitrate,” Journal of Cardiovascular Pharmacology, vol. 26, Supplement 3, pp. S497–S501, 1995.

[58] T. Münzel, T. Meinertz, U. Tebbe et al., “Efficacy of the long-acting nitrovasodilator pentaerithritol tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial,” European Heart Journal, vol. 35, no. 14, pp. 895–903, 2014.

[59] E. Schleussner, T. Lehmann, C. Kahler, U. Schneider, D. Schlembach, and T. Groten, “Impact of the nitric oxide donor pentaerythritol-tetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, double-blinded trial,” Journal of Perinatal Medicine, vol. 42, no. 4, pp. 507–514, 2014.

[60] I. Dovinova, S. Cacanyiova, V. Faberova, and F. Kristek, “The effect of an NO donor, pentaerythritol tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats,” General Physiology and Biophysics, vol. 28, no. 1, pp. 86–93, 2009.

[61] U. Flierl, D. Fraccarollo, J. D. Widder et al., “The nitric oxide donor pentaerythritol tetranitrate reduces platelet activation in congestive heart failure,” PLoS One, vol. 10, no. 4, article e0123621, 2015.

[62] D. Fraccarollo, P. Galuppo, J. Neuser, J. Bauersachs, and J. D. Widder, “Pentaerythritol tetranitrate targeting myocardial reactive oxygen species production improves left ventricular remodeling and function in rats with ischemic heart failure,” Hypertension, vol. 66, no. 5, pp. 978–987, 2015.

[63] S. Oberle, A. Abate, N. Grosser et al., “Endothelial protection by pentaerythritol trinitrate: bilirubin and carbon monoxide as possible mediators,” Experimental Biology and Medicine, vol. 228, no. 5, pp. 529–534, 2003.

[64] S. Oberle, A. Abate, N. Grosser et al., “Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythritol trinitrate,” Biochemical and Biophysical Research Communications, vol. 290, no. 5, pp. 1539–1544, 2002.

[65] S. Oberle and H. Schroder, “Ferritin may mediate SIN-1-induced protection against oxidative stress,” Nitric Oxide, vol. 1, no. 4, pp. 308–314, 1997.

[66] S. Oberle, P. Schwartz, A. Abate, and H. Schroder, “The antioxidative defense protein ferritin is a novel and specific target for pentaerithritol tetranitrate in endothelial cells,” Biochemical and Biophysical Research Communications, vol. 261, no. 1, pp. 28–34, 1999.

[67] M. Oppermann, V. Balz, V. Adams et al., “Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo,” Journal of Cellular and Molecular Medicine, vol. 13, no. 7, pp. 1271–1278, 2009.

[68] T. Thum, D. Fraccarollo, S. Thum et al., “Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 748–754, 2007.

[69] A. Daiber, M. Oelze, P. Wenzel, F. Bollmann, A. Pautz, and H. Kleintert, “Heme oxygenase-1 induction and organic nitrate therapy: beneficial effects on endothelial dysfunction, nitrate
tolerance, and vascular oxidative stress,” International Journal of Hypertension, vol. 2012, Article ID 842632, 13 pages, 2012.

[70] A. Pautz, P. Rauchkolb, N. Schmidt et al., “Effects of nitroglycerin or pentaerythritol tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardio-protective effects,” Physiological Genomics, vol. 38, no. 2, pp. 176–185, 2009.

[71] Z. Wu, D. Siuda, N. Xia et al., “Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring,” Hypertension, vol. 65, no. 1, pp. 232–237, 2015.

[72] A. Daiber and T. Munzel, “Characterization of the antioxidant properties of pentaerythritol tetranitrate (PETN)-induction of the intrinsic antioxidative system heme oxygenase-1 (HO-1),” Methods in Molecular Biology, vol. 594, pp. 311–326, 2010.

[73] A. Daiber, M. Oelze, M. Coldewey et al., “Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates,” Molecular Pharmacology, vol. 66, no. 6, pp. 1372–1382, 2004.

[74] T. Gori and A. Daiber, “Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerythrityl tetranitrate,” American Journal of Cardiovascular Drugs, vol. 9, no. 1, pp. 7–15, 2009.

[75] D. Nilsson, L. Gustafsson, A. Wackenfors et al., “Up-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathways,” BMC Cardiovascular Disorders, vol. 8, no. 1, p. 21, 2008.

[76] D. Ramzy, Y. Rao, L. C. Tumiati et al., “Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway,” Circulation, vol. 114, Supplement 1, pp. I319–I326, 2006.

[77] J. Stein, S. Steven, M. Bros et al., “Role of protein kinase C and Nox2-derived reactive oxygen species formation in the activation and maturation of dendritic cells by phorbol ester and lipopolysaccharide,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 4157213, 12 pages, 2017.

[78] S. Kroller-Schon, S. Steven, S. Kossmann et al., “Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models,” Antioxidants & Redox Signaling, vol. 20, no. 2, pp. 247–266, 2014.

[79] R. Radi, “Nitric oxide, oxidants, and protein tyrosine nitration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 12, pp. 4003–4008, 2004.

[80] D. R. Janero, N. S. Bryan, F. Saijo et al., “Differential nitros (yl) ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 48, pp. 16958–16963, 2004.

[81] A. Jabs, M. Oelze, Y. Mikhe et al., “Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats,” Vascular Pharmacology, vol. 71, pp. 181–191, 2015.

[82] J. N. Cohn, G. Johnson, S. Ziesche et al., “A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure,” The New England Journal of Medicine, vol. 325, no. 5, pp. 303–310, 1991.

[83] A. L. Taylor, S. Ziesche, C. Yancy et al., “Combination of isosorbide dinitrate and hydralazine in blacks with heart failure,” The New England Journal of Medicine, vol. 351, no. 20, pp. 2049–2057, 2004.

[84] J. M. Hare, “Nitroso-redox balance in the cardiovascular system,” The New England Journal of Medicine, vol. 351, no. 20, pp. 2112–2114, 2004.

[85] A. Daiber, M. Oelze, M. Coldewey et al., “Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure,” Biochemical and Biophysical Research Communications, vol. 338, no. 4, pp. 1865–1874, 2005.

[86] T. Munzel, S. Kurz, S. Rajagopalan et al., “Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug,” The Journal of Clinical Investigation, vol. 98, no. 6, pp. 1465–1470, 1996.

[87] M. Reriani, E. Raichlin, A. Prasad et al., “Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis,” Circulation, vol. 122, no. 10, pp. 958–966, 2010.

[88] E. Larose, D. Behrendt, S. Kinlay, A. P. Selwyn, P. Ganz, and J. C. Fang, “Endothelin-1 is a key mediator of coronary vasoconstriction in patients with transplant coronary arteriosclerosis,” Circulation. Heart Failure, vol. 2, no. 5, pp. 409–416, 2009.

[89] P. Wenzel, S. Kossmann, T. Munzel, and A. Daiber, “Redox regulation of cardiovascular inflammation - immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species,” Free Radical Biology & Medicine, vol. 109, pp. 48–60, 2017.

[90] S. Kroller-Schon, M. Knorr, M. Hausding et al., “Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition,” Cardiovascular Research, vol. 96, no. 1, pp. 140–149, 2012.